



Human Anti-Human CD80 / CD86 (Abatacept Biosimilar) monoclonal antibody, clone Abatacept (DMABB-JX595)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Specificity	Abatacept binds to CD80 (B7-1) with more avidity than to CD86 (B7-2). It inhibits the costimulation of T cells.
Isotype	IgG1
Source/Host	Human
Species Reactivity	Human
Clone	Abatacept
Purification	Affinity-purified. >95% by SDS-PAGE
Conjugate	Unconjugated
Applications	Functional Assays Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
Format	Purified, Liquid
Concentration	Lot specific
Size	1 mg, 5 mg, 10 mg, 20 mg
Buffer	PBS. 0.2 uM filtered solution, pH 7.2, no stabilizers or preservatives. Endotoxin ≤ 1.0 EU/mg

Preservative	None
Storage	For short-term storage, store at 2-8°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.

BACKGROUND

Introduction	Abatacept (Orencia, Bristol-Myers-Squibb) is a fusion protein of a Fc fragment (human IgG1 isotype) and the extracellular domain of CTLA-4, can be used to extend graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. Abatacept binds to CD80 (B7-1) with more avidity than to CD86 (B7-2). It inhibits the costimulation of T cells. Abatacept differs from belatacept (trade name Nulojix) by only 2 amino acids.
Keywords	Abatacept, Orencia, Bristol-Myers-Squibb